Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,711
archived clinical trials in
Depression

Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Allentown, PA
Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Allentown, PA
Click here to add this to my saved trials
Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial
Status: Enrolling
Updated:  12/31/1969
mi
from
Bala-Cynwyd, PA
Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial
Status: Enrolling
Updated: 12/31/1969
mi
from
Bala-Cynwyd, PA
Click here to add this to my saved trials
Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Bridgeville, PA
Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Bridgeville, PA
Click here to add this to my saved trials
Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Norristown, PA
Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Norristown, PA
Click here to add this to my saved trials
Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Columbia, SC
Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Columbia, SC
Click here to add this to my saved trials
Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Arlington, TX
Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Arlington, TX
Click here to add this to my saved trials
Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Austin, TX
Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Middleton, WI
Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Middleton, WI
Click here to add this to my saved trials
Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial
Status: Enrolling
Updated:  12/31/1969
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
mi
from
Gatineau,
Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial
Status: Enrolling
Updated: 12/31/1969
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
mi
from
Gatineau,
Click here to add this to my saved trials
VITAL-DEP: Depression Endpoint Prevention in the VITamin D and OmegA-3 TriaL
VITAL-DEP: Depression Endpoint Prevention in the VITamin D and OmegA-3 TriaL
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
VITAL-DEP: Depression Endpoint Prevention in the VITamin D and OmegA-3 TriaL
VITAL-DEP: Depression Endpoint Prevention in the VITamin D and OmegA-3 TriaL
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Open Label Extension for GLYX13-C-202, NCT01684163
Phase 2, Open Label Extension for Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder Previously Treated With GLYX-13 (Extension of GLYX13-C-202, NCT01684163)
Status: Enrolling
Updated:  12/31/1969
Office of Psychiatric Research
mi
from
Birmingham, AL
Open Label Extension for GLYX13-C-202, NCT01684163
Phase 2, Open Label Extension for Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder Previously Treated With GLYX-13 (Extension of GLYX13-C-202, NCT01684163)
Status: Enrolling
Updated: 12/31/1969
Office of Psychiatric Research
mi
from
Birmingham, AL
Click here to add this to my saved trials
Open Label Extension for GLYX13-C-202, NCT01684163
Phase 2, Open Label Extension for Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder Previously Treated With GLYX-13 (Extension of GLYX13-C-202, NCT01684163)
Status: Enrolling
Updated:  12/31/1969
Artemis Institute for Clinical Research
mi
from
San Diego, CA
Open Label Extension for GLYX13-C-202, NCT01684163
Phase 2, Open Label Extension for Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder Previously Treated With GLYX-13 (Extension of GLYX13-C-202, NCT01684163)
Status: Enrolling
Updated: 12/31/1969
Artemis Institute for Clinical Research
mi
from
San Diego, CA
Click here to add this to my saved trials
Open Label Extension for GLYX13-C-202, NCT01684163
Phase 2, Open Label Extension for Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder Previously Treated With GLYX-13 (Extension of GLYX13-C-202, NCT01684163)
Status: Enrolling
Updated:  12/31/1969
Chicago Research Center, Inc
mi
from
Chicago, IL
Open Label Extension for GLYX13-C-202, NCT01684163
Phase 2, Open Label Extension for Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder Previously Treated With GLYX-13 (Extension of GLYX13-C-202, NCT01684163)
Status: Enrolling
Updated: 12/31/1969
Chicago Research Center, Inc
mi
from
Chicago, IL
Click here to add this to my saved trials
Open Label Extension for GLYX13-C-202, NCT01684163
Phase 2, Open Label Extension for Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder Previously Treated With GLYX-13 (Extension of GLYX13-C-202, NCT01684163)
Status: Enrolling
Updated:  12/31/1969
University of Kansas School of Medicine Clinical Trial Unit
mi
from
Wichita, KA
Open Label Extension for GLYX13-C-202, NCT01684163
Phase 2, Open Label Extension for Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder Previously Treated With GLYX-13 (Extension of GLYX13-C-202, NCT01684163)
Status: Enrolling
Updated: 12/31/1969
University of Kansas School of Medicine Clinical Trial Unit
mi
from
Wichita, KA
Click here to add this to my saved trials
Open Label Extension for GLYX13-C-202, NCT01684163
Phase 2, Open Label Extension for Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder Previously Treated With GLYX-13 (Extension of GLYX13-C-202, NCT01684163)
Status: Enrolling
Updated:  12/31/1969
Pharmasite Research
mi
from
Baltimore, MD
Open Label Extension for GLYX13-C-202, NCT01684163
Phase 2, Open Label Extension for Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder Previously Treated With GLYX-13 (Extension of GLYX13-C-202, NCT01684163)
Status: Enrolling
Updated: 12/31/1969
Pharmasite Research
mi
from
Baltimore, MD
Click here to add this to my saved trials
Open Label Extension for GLYX13-C-202, NCT01684163
Phase 2, Open Label Extension for Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder Previously Treated With GLYX-13 (Extension of GLYX13-C-202, NCT01684163)
Status: Enrolling
Updated:  12/31/1969
Boston Clinical Trials, Inc.
mi
from
Roslindale, MA
Open Label Extension for GLYX13-C-202, NCT01684163
Phase 2, Open Label Extension for Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder Previously Treated With GLYX-13 (Extension of GLYX13-C-202, NCT01684163)
Status: Enrolling
Updated: 12/31/1969
Boston Clinical Trials, Inc.
mi
from
Roslindale, MA
Click here to add this to my saved trials
Open Label Extension for GLYX13-C-202, NCT01684163
Phase 2, Open Label Extension for Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder Previously Treated With GLYX-13 (Extension of GLYX13-C-202, NCT01684163)
Status: Enrolling
Updated:  12/31/1969
Woodlands Professional Princeton Medical Institute Building
mi
from
Princeton, NJ
Open Label Extension for GLYX13-C-202, NCT01684163
Phase 2, Open Label Extension for Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder Previously Treated With GLYX-13 (Extension of GLYX13-C-202, NCT01684163)
Status: Enrolling
Updated: 12/31/1969
Woodlands Professional Princeton Medical Institute Building
mi
from
Princeton, NJ
Click here to add this to my saved trials
Open Label Extension for GLYX13-C-202, NCT01684163
Phase 2, Open Label Extension for Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder Previously Treated With GLYX-13 (Extension of GLYX13-C-202, NCT01684163)
Status: Enrolling
Updated:  12/31/1969
Finger Lake Clinical Research
mi
from
Rochester, NY
Open Label Extension for GLYX13-C-202, NCT01684163
Phase 2, Open Label Extension for Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder Previously Treated With GLYX-13 (Extension of GLYX13-C-202, NCT01684163)
Status: Enrolling
Updated: 12/31/1969
Finger Lake Clinical Research
mi
from
Rochester, NY
Click here to add this to my saved trials
Open Label Extension for GLYX13-C-202, NCT01684163
Phase 2, Open Label Extension for Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder Previously Treated With GLYX-13 (Extension of GLYX13-C-202, NCT01684163)
Status: Enrolling
Updated:  12/31/1969
Lindner Center of HOPE
mi
from
Mason, OH
Open Label Extension for GLYX13-C-202, NCT01684163
Phase 2, Open Label Extension for Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder Previously Treated With GLYX-13 (Extension of GLYX13-C-202, NCT01684163)
Status: Enrolling
Updated: 12/31/1969
Lindner Center of HOPE
mi
from
Mason, OH
Click here to add this to my saved trials
Open Label Extension for GLYX13-C-202, NCT01684163
Phase 2, Open Label Extension for Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder Previously Treated With GLYX-13 (Extension of GLYX13-C-202, NCT01684163)
Status: Enrolling
Updated:  12/31/1969
PRA Health Sciences Phase 2/3 Outpatient & CNS Clinic
mi
from
Salt Lake City, UT
Open Label Extension for GLYX13-C-202, NCT01684163
Phase 2, Open Label Extension for Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder Previously Treated With GLYX-13 (Extension of GLYX13-C-202, NCT01684163)
Status: Enrolling
Updated: 12/31/1969
PRA Health Sciences Phase 2/3 Outpatient & CNS Clinic
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
The Effect of Questionnaire Content on Measures of Pain Intensity, Magnitude of Disability, and Symptoms of Depression in Patients With Arm Illness
The Effect of Questionnaire Content on Measures of Pain Intensity, Magnitude of Disability, and Symptoms of Depression in Patients With Arm Illness
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
The Effect of Questionnaire Content on Measures of Pain Intensity, Magnitude of Disability, and Symptoms of Depression in Patients With Arm Illness
The Effect of Questionnaire Content on Measures of Pain Intensity, Magnitude of Disability, and Symptoms of Depression in Patients With Arm Illness
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Person-Centered Versus Measurement-Based Care in Mental Health
Amplifying the Patient's Voice: Person-Centered Versus Measurement-Based Approaches in Mental Health
Status: Enrolling
Updated:  12/31/1969
Dartmouth Psychiatric Research Center
mi
from
Lebanon, NH
Person-Centered Versus Measurement-Based Care in Mental Health
Amplifying the Patient's Voice: Person-Centered Versus Measurement-Based Approaches in Mental Health
Status: Enrolling
Updated: 12/31/1969
Dartmouth Psychiatric Research Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Person-Centered Versus Measurement-Based Care in Mental Health
Amplifying the Patient's Voice: Person-Centered Versus Measurement-Based Approaches in Mental Health
Status: Enrolling
Updated:  12/31/1969
UPMC Center for High-Value Health Care
mi
from
Pittsburgh, PA
Person-Centered Versus Measurement-Based Care in Mental Health
Amplifying the Patient's Voice: Person-Centered Versus Measurement-Based Approaches in Mental Health
Status: Enrolling
Updated: 12/31/1969
UPMC Center for High-Value Health Care
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Biological Triggers of Depression in Pregnancy
The Role of Kynurenine Pathway Metabolites in Perinatal Depression and Suicidality
Status: Enrolling
Updated:  12/31/1969
Spectrum Health System
mi
from
Grand Rapids, MI
Biological Triggers of Depression in Pregnancy
The Role of Kynurenine Pathway Metabolites in Perinatal Depression and Suicidality
Status: Enrolling
Updated: 12/31/1969
Spectrum Health System
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Biological Triggers of Depression in Pregnancy
The Role of Kynurenine Pathway Metabolites in Perinatal Depression and Suicidality
Status: Enrolling
Updated:  12/31/1969
Van Andel Research Institute
mi
from
Grand Rapids, MI
Biological Triggers of Depression in Pregnancy
The Role of Kynurenine Pathway Metabolites in Perinatal Depression and Suicidality
Status: Enrolling
Updated: 12/31/1969
Van Andel Research Institute
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Biological Triggers of Depression in Pregnancy
The Role of Kynurenine Pathway Metabolites in Perinatal Depression and Suicidality
Status: Enrolling
Updated:  12/31/1969
Pine Rest Christian Mental Health Services
mi
from
Grand rapids, MI
Biological Triggers of Depression in Pregnancy
The Role of Kynurenine Pathway Metabolites in Perinatal Depression and Suicidality
Status: Enrolling
Updated: 12/31/1969
Pine Rest Christian Mental Health Services
mi
from
Grand rapids, MI
Click here to add this to my saved trials
Ketamine for Depression: An MRI Study
Baseline Insular Dysfunction as a Predictor of Ketamine's Antidepressant Effects in Anxious Depression
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Ketamine for Depression: An MRI Study
Baseline Insular Dysfunction as a Predictor of Ketamine's Antidepressant Effects in Anxious Depression
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
The Efficacy of Cranial Electrostimulating Therapy for Depression and Anxiety Among Homeless Adults
The Efficacy of Cranial Electrostimulating Therapy for Depression and Anxiety
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
The Efficacy of Cranial Electrostimulating Therapy for Depression and Anxiety Among Homeless Adults
The Efficacy of Cranial Electrostimulating Therapy for Depression and Anxiety
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Quantified Mobile Sensing for Improving Diagnosis and Measuring Disease Progression
Quantified Mobile Sensing for Improving Diagnosis and Measuring Disease Progression
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Quantified Mobile Sensing for Improving Diagnosis and Measuring Disease Progression
Quantified Mobile Sensing for Improving Diagnosis and Measuring Disease Progression
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Bipolar Proteomic Assay Validation Study
A Validation Study to Measure the Impact of a Proteomic Assay in Distinguishing Bipolar I Disorder, Bipolar II Disorder, and Major Depressive Disorder in People Presenting With a Major Depressive Episode
Status: Enrolling
Updated:  12/31/1969
University of Minnesota (UMN) Department of Psychiatry
mi
from
Minneapolis, MN
Bipolar Proteomic Assay Validation Study
A Validation Study to Measure the Impact of a Proteomic Assay in Distinguishing Bipolar I Disorder, Bipolar II Disorder, and Major Depressive Disorder in People Presenting With a Major Depressive Episode
Status: Enrolling
Updated: 12/31/1969
University of Minnesota (UMN) Department of Psychiatry
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Bipolar Proteomic Assay Validation Study
A Validation Study to Measure the Impact of a Proteomic Assay in Distinguishing Bipolar I Disorder, Bipolar II Disorder, and Major Depressive Disorder in People Presenting With a Major Depressive Episode
Status: Enrolling
Updated:  12/31/1969
Lindner Center of HOPE/University of Cincinnati College of Medicine
mi
from
Mason, OH
Bipolar Proteomic Assay Validation Study
A Validation Study to Measure the Impact of a Proteomic Assay in Distinguishing Bipolar I Disorder, Bipolar II Disorder, and Major Depressive Disorder in People Presenting With a Major Depressive Episode
Status: Enrolling
Updated: 12/31/1969
Lindner Center of HOPE/University of Cincinnati College of Medicine
mi
from
Mason, OH
Click here to add this to my saved trials
Bipolar Proteomic Assay Validation Study
A Validation Study to Measure the Impact of a Proteomic Assay in Distinguishing Bipolar I Disorder, Bipolar II Disorder, and Major Depressive Disorder in People Presenting With a Major Depressive Episode
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Science Center
mi
from
San Antonio, TX
Bipolar Proteomic Assay Validation Study
A Validation Study to Measure the Impact of a Proteomic Assay in Distinguishing Bipolar I Disorder, Bipolar II Disorder, and Major Depressive Disorder in People Presenting With a Major Depressive Episode
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Science Center
mi
from
San Antonio, TX
Click here to add this to my saved trials
Bipolar Proteomic Assay Validation Study
A Validation Study to Measure the Impact of a Proteomic Assay in Distinguishing Bipolar I Disorder, Bipolar II Disorder, and Major Depressive Disorder in People Presenting With a Major Depressive Episode
Status: Enrolling
Updated:  12/31/1969
University of Iowa Health Care, Department of Psychiatry
mi
from
Iowa City, IA
Bipolar Proteomic Assay Validation Study
A Validation Study to Measure the Impact of a Proteomic Assay in Distinguishing Bipolar I Disorder, Bipolar II Disorder, and Major Depressive Disorder in People Presenting With a Major Depressive Episode
Status: Enrolling
Updated: 12/31/1969
University of Iowa Health Care, Department of Psychiatry
mi
from
Iowa City, IA
Click here to add this to my saved trials
Bipolar Proteomic Assay Validation Study
A Validation Study to Measure the Impact of a Proteomic Assay in Distinguishing Bipolar I Disorder, Bipolar II Disorder, and Major Depressive Disorder in People Presenting With a Major Depressive Episode
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh, Western Psychiatric Institute and Clinic
mi
from
Pittsburgh, PA
Bipolar Proteomic Assay Validation Study
A Validation Study to Measure the Impact of a Proteomic Assay in Distinguishing Bipolar I Disorder, Bipolar II Disorder, and Major Depressive Disorder in People Presenting With a Major Depressive Episode
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh, Western Psychiatric Institute and Clinic
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Cognitive Recovery After Electroconvulsive Therapy and General Anesthesia
Cognitive Recovery After Electroconvulsive Therapy and General Anesthesia Reconstitution of Consciousness and Cognition (Phase 2)
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Cognitive Recovery After Electroconvulsive Therapy and General Anesthesia
Cognitive Recovery After Electroconvulsive Therapy and General Anesthesia Reconstitution of Consciousness and Cognition (Phase 2)
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Increasing Physical Activity Among Breast Cancer Survivors With Depression
Increasing Physical Activity Among Breast Cancer Survivors With Depression
Status: Enrolling
Updated:  12/31/1969
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Increasing Physical Activity Among Breast Cancer Survivors With Depression
Increasing Physical Activity Among Breast Cancer Survivors With Depression
Status: Enrolling
Updated: 12/31/1969
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
IntelliCare Study: Artificial Intelligence in a Mobile (AIM) Intervention for Depression
Artificial Intelligence in a Mobile (AIM) Intervention for Depression
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
IntelliCare Study: Artificial Intelligence in a Mobile (AIM) Intervention for Depression
Artificial Intelligence in a Mobile (AIM) Intervention for Depression
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
NeoSync TMS Treatment for Bipolar I Depression
Evaluation of NeoSync EEG Synchronized TMS For the Treatment of Major Depressive Episode in Bipolar Disorder and Associated Neural Response: An Open Label Trial
Status: Enrolling
Updated:  12/31/1969
Butler Hospital
mi
from
Providence, RI
NeoSync TMS Treatment for Bipolar I Depression
Evaluation of NeoSync EEG Synchronized TMS For the Treatment of Major Depressive Episode in Bipolar Disorder and Associated Neural Response: An Open Label Trial
Status: Enrolling
Updated: 12/31/1969
Butler Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Augmentation of Treatment-Resistant Depression With An Analog of the Neuroactive Steroid Allopregnanolone
Treatment-Resistant Depression Augmentation Therapy With An Analog of the Neuroactive Steroid Allopregnanolone: A Pilot Study
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Augmentation of Treatment-Resistant Depression With An Analog of the Neuroactive Steroid Allopregnanolone
Treatment-Resistant Depression Augmentation Therapy With An Analog of the Neuroactive Steroid Allopregnanolone: A Pilot Study
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home
MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home - A Pilot Study
Status: Enrolling
Updated:  12/31/1969
Cambridge Health Alliance Center for Mindfulness and Compassion
mi
from
Somerville, MA
MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home
MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home - A Pilot Study
Status: Enrolling
Updated: 12/31/1969
Cambridge Health Alliance Center for Mindfulness and Compassion
mi
from
Somerville, MA
Click here to add this to my saved trials
Anxiety With Cancer in the Elderly (ACE): A Cognitive-behavioral Intervention
Anxiety With Cancer in the Elderly (ACE): A Cognitive-behavioral Intervention
Status: Enrolling
Updated:  12/31/1969
Weill Medical College of Cornell University
mi
from
New York, NY
Anxiety With Cancer in the Elderly (ACE): A Cognitive-behavioral Intervention
Anxiety With Cancer in the Elderly (ACE): A Cognitive-behavioral Intervention
Status: Enrolling
Updated: 12/31/1969
Weill Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)
Interventional, Randomised, Double-blind, Placebo-controlled, Active Reference (Fluoxetine), Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years, With Major Depressive Disorder (MDD)
Status: Enrolling
Updated:  12/31/1969
US1369
mi
from
Dothan, AL
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)
Interventional, Randomised, Double-blind, Placebo-controlled, Active Reference (Fluoxetine), Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years, With Major Depressive Disorder (MDD)
Status: Enrolling
Updated: 12/31/1969
US1369
mi
from
Dothan, AL
Click here to add this to my saved trials
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)
Interventional, Randomised, Double-blind, Placebo-controlled, Active Reference (Fluoxetine), Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years, With Major Depressive Disorder (MDD)
Status: Enrolling
Updated:  12/31/1969
US1310
mi
from
Little Rock, AR
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)
Interventional, Randomised, Double-blind, Placebo-controlled, Active Reference (Fluoxetine), Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years, With Major Depressive Disorder (MDD)
Status: Enrolling
Updated: 12/31/1969
US1310
mi
from
Little Rock, AR
Click here to add this to my saved trials
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)
Interventional, Randomised, Double-blind, Placebo-controlled, Active Reference (Fluoxetine), Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years, With Major Depressive Disorder (MDD)
Status: Enrolling
Updated:  12/31/1969
US1062
mi
from
Costa Mesa, CA
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)
Interventional, Randomised, Double-blind, Placebo-controlled, Active Reference (Fluoxetine), Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years, With Major Depressive Disorder (MDD)
Status: Enrolling
Updated: 12/31/1969
US1062
mi
from
Costa Mesa, CA
Click here to add this to my saved trials
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)
Interventional, Randomised, Double-blind, Placebo-controlled, Active Reference (Fluoxetine), Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years, With Major Depressive Disorder (MDD)
Status: Enrolling
Updated:  12/31/1969
US1387
mi
from
Downey, CA
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)
Interventional, Randomised, Double-blind, Placebo-controlled, Active Reference (Fluoxetine), Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years, With Major Depressive Disorder (MDD)
Status: Enrolling
Updated: 12/31/1969
US1387
mi
from
Downey, CA
Click here to add this to my saved trials
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)
Interventional, Randomised, Double-blind, Placebo-controlled, Active Reference (Fluoxetine), Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years, With Major Depressive Disorder (MDD)
Status: Enrolling
Updated:  12/31/1969
US1118
mi
from
Glendale, CA
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)
Interventional, Randomised, Double-blind, Placebo-controlled, Active Reference (Fluoxetine), Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years, With Major Depressive Disorder (MDD)
Status: Enrolling
Updated: 12/31/1969
US1118
mi
from
Glendale, CA
Click here to add this to my saved trials
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)
Interventional, Randomised, Double-blind, Placebo-controlled, Active Reference (Fluoxetine), Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years, With Major Depressive Disorder (MDD)
Status: Enrolling
Updated:  12/31/1969
US1368
mi
from
Orange, CA
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)
Interventional, Randomised, Double-blind, Placebo-controlled, Active Reference (Fluoxetine), Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years, With Major Depressive Disorder (MDD)
Status: Enrolling
Updated: 12/31/1969
US1368
mi
from
Orange, CA
Click here to add this to my saved trials
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)
Interventional, Randomised, Double-blind, Placebo-controlled, Active Reference (Fluoxetine), Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years, With Major Depressive Disorder (MDD)
Status: Enrolling
Updated:  12/31/1969
US1370
mi
from
Panorama City, CA
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)
Interventional, Randomised, Double-blind, Placebo-controlled, Active Reference (Fluoxetine), Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years, With Major Depressive Disorder (MDD)
Status: Enrolling
Updated: 12/31/1969
US1370
mi
from
Panorama City, CA
Click here to add this to my saved trials